Sodium Fluoride PET/CT in Clinical Use
37,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in 6-10 Tagen
  • Broschiertes Buch

This pocket book is the first of its kind on sodium fluoride (18F-NaF)-PET and addresses skeletal as well as cardiovascular applications. In malignant metastatic diseases 18F-NaF-PET has already demonstrated its benefits in cancer staging, re-staging, follow-up and response evaluation. It also has an emerging diagnostic role in the calcified soft-tissue metastases of primary bone tumours, and can be applied to evaluate cardiovascular diseases, such as calcifications in heart valves and peripheral vascular disease. The book is divided into 11 chapters: five on oncology, four addressing the…mehr

Andere Kunden interessierten sich auch für
Produktbeschreibung
This pocket book is the first of its kind on sodium fluoride (18F-NaF)-PET and addresses skeletal as well as cardiovascular applications. In malignant metastatic diseases 18F-NaF-PET has already demonstrated its benefits in cancer staging, re-staging, follow-up and response evaluation. It also has an emerging diagnostic role in the calcified soft-tissue metastases of primary bone tumours, and can be applied to evaluate cardiovascular diseases, such as calcifications in heart valves and peripheral vascular disease.
The book is divided into 11 chapters: five on oncology, four addressing the general aspects of skeletal conditions, and two on cardiovascular diseases. It offers a valuable guide for referring colleagues, nuclear medicine physicians/radiologists and aid clinicians, and highlights the main applications and limitations of 18F-NaF-PET hybrid imaging (PET/CT).

Autorenporträt
Prof. Kairemo graduated with an MSc (Eng) degree from Helsinki University of Technology in 1980 before undertaking medical training (MD, PhD) at the University of Helsinki, Finland. He subsequently completed specialist training in Clinical Chemistry, Nuclear Medicine and Clinical Pharmacology at Helsinki University Central Hospital (HUCH), followed by a research fellowship at Memorial Sloan-Kettering Cancer Center in New York (1989-93).   He has held posts as Professor of Clinical Chemistry at the Norwegian University of Science and Technology (1998-99), Professor of Nuclear Medicine at Uppsala University Hospital in Sweden (2001-05) and as Head of the Nuclear Medicine Division, Department of Oncology at HUCH (2004-09). From 2009 to 2018, he was Chief of Nuclear Medicine and Molecular Radiotherapy at the Docrates Cancer Center in Helsinki.  Since 2015 he has also been a Visiting Professor (Nuclear Medicine) at the University of Texas MD Anderson Cancer Center.   Besides holding a few patents he has published more than 200 original articles in peer-reviewed journals. In 2012, he received the Lifetime Achievement Award from the World Association of Radiopharmaceutical and Molecular Therapy.            Dr. Homer A. Macapinlac is the James E. Anderson Distinguished Professor of Nuclear Medicine and Chair of the Department of Nuclear Medicine at the University of Texas M.D. Anderson Cancer Center in Houston, Texas. Dr. Macapinlac is certified by the American Board of Nuclear Medicine, with a Certificate of Added Qualification (CAQ) in Nuclear Cardiology. He was also elected as a fellow of the American College of Nuclear Physicians. Prior to coming to M. D. Anderson, he served as clinical director of the Laurent and Alberta Gershel Positron Emission Tomography Center of Memorial Sloan¿Kettering Cancer Center, New York. Dr. Macapinlac is an active committee member of various groups, and has served as past¿Chair of the Institute of Clinical PET. He was Chair of the Society of Nuclear Medicine PET Center of Excellence and received the SNM Distinguished Service Award for this role. Dr. Macapinlac is also an expert consultant to the IAEA, and an International Visiting Professor for the Radiological Society of North America. He has 199 peer reviewed publications with 11,751 citations and h-Index of 57.